Importantly, when we tested six other selective ALK inhibitors on our tumor model collection, we found that ceritinib was by far the most efficacious compound, comparably strong to doxorubicin and much stronger than cisplatin, the standard-of-care therapeutics for HB (Fig. 2G and H). Here, ALK is linked to neoplasm.